+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series



Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series



Annals of Surgery 258(3): 466-475



The aim of this study was to critically analyze the safety of the revised guidelines, with focus on cyst size and worrisome features in the management of BD-IPMN. The Sendai guidelines for management of branch duct (BD) intraductal papillary mucinous neoplasm (IPMN) espouse safety of observation of asymptomatic cysts smaller than 3 cm without nodules (Sendai negative). Revised international consensus guidelines published in 2012 suggest a still more conservative approach, even for lesions of 3 cm or larger. By contrast, 2 recent studies have challenged the safety of both guidelines, describing invasive carcinoma or carcinoma in situ in 67% of BD-IPMN smaller than 3 cm and in 25% of "Sendai-negative" BD-IPMN. Review of a prospective database identified 563 patients with BD-IPMN. A total of 240 patients underwent surgical resection (152 at the time of diagnosis and 88 after being initially followed); the remaining 323 have been managed by observation with median follow-up of 60 months. No patient developed unresectable BD-IPMN carcinoma during follow-up. Invasive cancer arising in BD-IPMN was found in 23 patients of the entire cohort (4%), and an additional 21 patients (3.7%) had or developed concurrent pancreatic ductal adenocarcinoma. According to the revised guidelines, 76% of resected BD-IPMN with carcinoma in situ and 95% of resected BD-IPMN with invasive cancer had high-risk stigmata or worrisome features. The risk of high-grade dysplasia in nonworrisome lesions smaller than 3 cm was 6.5%, but when the threshold was raised to greater than 3 cm, it was 8.8%, and 1 case of invasive carcinoma was found. Expectant management of BD-IPMN following the old guidelines is safe, whereas caution is advised for larger lesions, even in the absence of worrisome features.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051859256

Download citation: RISBibTeXText

PMID: 24022439

DOI: 10.1097/sla.0b013e3182a18f48


Related references

Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. Journal of the American College of Surgeons 220(2): 243-253, 2015

Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery 16(3): 353-358, 2009

Tu1510 Validation of the International Consensus Guidelines for Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Meta-Analysis. Gastroenterology 142(5): S-852-S-853, 2012

Validation of the 2012 International Consensus Guidelines Using CT and MRI: Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery 266(6): E51-E52, 2017

Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. British Journal of Surgery 101(6): 686-692, 2014

Pancreatic-duct-lavage cytology in candidates for surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas: should the International Consensus Guidelines be revised?. Gastrointestinal Endoscopy 69(3 Pt 1): 434-440, 2009

Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas. United European Gastroenterology Journal 4(4): 580-586, 2016

Validation of the 2012 International Consensus Guidelines Using Computed Tomography and Magnetic Resonance Imaging: Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery 263(3): 557-564, 2016

"High-risk stigmata" of the 2012 international consensus guidelines correlate with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas 43(8): 1239-1243, 2014

Utility of the sendai consensus guidelines for branch-duct intraductal papillary mucinous neoplasms: a systematic review. Journal of Gastrointestinal Surgery 18(7): 1350-1357, 2014

S1297 When to Operate or Observe Branch Duct Intraductal Papillary Mucinous Neoplasms (Ipmn-Br): Evaluation of Consensus Guidelines. Gastroenterology 136(5): A-232, 2009

Risk Factors for Malignancy of Branch-Duct Intraductal Papillary Mucinous Neoplasms: A Critical Evaluation of the Fukuoka Guidelines With a Systematic Review and Meta-analysis. Pancreas 45(9): 1243-1254, 2016

Does cyst growth predict malignancy in branch duct intraductal papillary mucinous neoplasms? Results of a large multicenter experience. Digestive and Liver Disease 50(9): 961-968, 2018

Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis. Digestive Diseases and Sciences 55(3): 852-860, 2010

Su1472 Follow up of Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas With a Cyst Over 30mm in Diameter: A Single Center Experience. Gastroenterology 148(4): S-522, 2015